Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2014 1
2015 4
2016 1
2017 3
2018 3
2019 2
2020 2
2021 1
2022 0
Text availability
Article attribute
Article type
Publication date

Search Results

17 results
Results by year
Filters applied: . Clear all
Page 1
TREM2 Modulation Remodels the Tumor Myeloid Landscape Enhancing Anti-PD-1 Immunotherapy.
Molgora M, Esaulova E, Vermi W, Hou J, Chen Y, Luo J, Brioschi S, Bugatti M, Omodei AS, Ricci B, Fronick C, Panda SK, Takeuchi Y, Gubin MM, Faccio R, Cella M, Gilfillan S, Unanue ER, Artyomov MN, Schreiber RD, Colonna M. Molgora M, et al. Cell. 2020 Aug 20;182(4):886-900.e17. doi: 10.1016/j.cell.2020.07.013. Epub 2020 Aug 11. Cell. 2020. PMID: 32783918 Free PMC article.
MHC-II neoantigens shape tumour immunity and response to immunotherapy.
Alspach E, Lussier DM, Miceli AP, Kizhvatov I, DuPage M, Luoma AM, Meng W, Lichti CF, Esaulova E, Vomund AN, Runci D, Ward JP, Gubin MM, Medrano RFV, Arthur CD, White JM, Sheehan KCF, Chen A, Wucherpfennig KW, Jacks T, Unanue ER, Artyomov MN, Schreiber RD. Alspach E, et al. Nature. 2019 Oct;574(7780):696-701. doi: 10.1038/s41586-019-1671-8. Epub 2019 Oct 23. Nature. 2019. PMID: 31645760 Free PMC article.
High-Dimensional Analysis Delineates Myeloid and Lymphoid Compartment Remodeling during Successful Immune-Checkpoint Cancer Therapy.
Gubin MM, Esaulova E, Ward JP, Malkova ON, Runci D, Wong P, Noguchi T, Arthur CD, Meng W, Alspach E, Medrano RFV, Fronick C, Fehlings M, Newell EW, Fulton RS, Sheehan KCF, Oh ST, Schreiber RD, Artyomov MN. Gubin MM, et al. Cell. 2018 Nov 1;175(4):1014-1030.e19. doi: 10.1016/j.cell.2018.09.030. Epub 2018 Oct 18. Cell. 2018. PMID: 30343900 Free PMC article.
WDFY4 is required for cross-presentation in response to viral and tumor antigens.
Theisen DJ, Davidson JT 4th, Briseño CG, Gargaro M, Lauron EJ, Wang Q, Desai P, Durai V, Bagadia P, Brickner JR, Beatty WL, Virgin HW, Gillanders WE, Mosammaparast N, Diamond MS, Sibley LD, Yokoyama W, Schreiber RD, Murphy TL, Murphy KM. Theisen DJ, et al. Science. 2018 Nov 9;362(6415):694-699. doi: 10.1126/science.aat5030. Science. 2018. PMID: 30409884 Free PMC article.
Checkpoint blockade cancer immunotherapy targets tumour-specific mutant antigens.
Gubin MM, Zhang X, Schuster H, Caron E, Ward JP, Noguchi T, Ivanova Y, Hundal J, Arthur CD, Krebber WJ, Mulder GE, Toebes M, Vesely MD, Lam SS, Korman AJ, Allison JP, Freeman GJ, Sharpe AH, Pearce EL, Schumacher TN, Aebersold R, Rammensee HG, Melief CJ, Mardis ER, Gillanders WE, Artyomov MN, Schreiber RD. Gubin MM, et al. Nature. 2014 Nov 27;515(7528):577-81. doi: 10.1038/nature13988. Nature. 2014. PMID: 25428507 Free PMC article.
cDC1 prime and are licensed by CD4+ T cells to induce anti-tumour immunity.
Ferris ST, Durai V, Wu R, Theisen DJ, Ward JP, Bern MD, Davidson JT 4th, Bagadia P, Liu T, Briseño CG, Li L, Gillanders WE, Wu GF, Yokoyama WM, Murphy TL, Schreiber RD, Murphy KM. Ferris ST, et al. Nature. 2020 Aug;584(7822):624-629. doi: 10.1038/s41586-020-2611-3. Epub 2020 Aug 12. Nature. 2020. PMID: 32788723 Free PMC article.
17 results